SQK

Investor White Paper 2026

Validated Quantum-AI-HPC Platform for High-Trust Medical Imaging and Scientific Computing

Positioning Statement

SQK builds validated, secure, and deployable advanced-computing solutions for high-trust industries. The company leads with QMedic as its focused commercial product for medical imaging workflows, supported by an integrated Quantum-AI-HPC platform for validation, orchestration, and physics-informed modeling.

Item	Description
Company	SQK
Primary Commercial Product	QMedic
Platform Foundation	SQK Quantum-AI-HPC Platform: QTAU validation, Qukkos orchestration, QPINN physics-informed modeling, and SuperQuantumStation ecosystem access
Primary Investment Narrative	Focused medical imaging wedge with reusable platform assets for high-trust industries
Document Type	Investor / Partner White Paper
Version / Date	Public Release v1.0 / 2026-05-17

Important Notice: This document is provided for investor and partner information only. It is not an offer to sell or a solicitation to buy securities. Forward-looking statements are subject to business, technical, regulatory, market, and financing risks. Medical imaging products and related workflows must be evaluated within the applicable regulatory and clinical-use framework before clinical deployment.

Table of Contents

1. Executive Summary
2. Investment Highlights
3. Company Overview and Market Context
4. Product Focus: QMedic
5. Platform Foundation Behind QMedic

6. Technology Architecture and Differentiation
7. Milestones and Validation Narrative
8. Business Model and Go-to-Market Strategy
9. Growth Roadmap and Use of Proceeds
10. Risk Management
11. Investor Thesis and Conclusion
Appendix A. One-Page Investor Summary

1. Executive Summary

SQK is a Quantum-AI-HPC platform company focused on high-trust industries where reliability, reproducibility, explainability, and secure deployment are central to adoption. The company's investor story is intentionally focused: QMedic is the lead commercial product, and the broader platform provides the trust, orchestration, and modeling capabilities that make QMedic scalable and defensible.

QMedic applies SQK's technology stack to medical imaging workflows such as CT/MRI-oriented reconstruction, refinement, comparison, and quality governance. This gives investors a clear market entry point instead of a confusing list of unrelated products.

Core Message

SQK is not presenting five separate products. SQK is presenting one focused commercial wedge, QMedic, backed by a reusable Quantum-AI-HPC platform that can expand into scientific computing, industrial optimization, and secure medical AI.

2. Investment Highlights

Theme	Investor Message	Business Implication
Focused wedge	QMedic is the lead commercial story for investors.	A concrete workflow in high-trust medical imaging creates a clearer path to pilots, SaaS/API packaging, and enterprise licensing.
Reusable platform	QTAU, Qukkos, QPINN, and SuperQuantumStation are presented as enabling platform assets, not competing product narratives.	The platform supports lower marginal expansion cost and stronger technical leverage across future verticals.
Trust layer	QTAU converts advanced-computing claims into measurable validation, benchmark, and quality-governance evidence.	Trust evidence helps customers evaluate adoption before large-scale deployment.
Hybrid execution	Qukkos supports quantum-classical-HPC workflow orchestration as enterprise workloads become more hybrid.	This creates future enterprise infrastructure and integration opportunities.
Physics-informed modeling	QPINN supports domains where black-box AI is insufficient and physics constraints improve confidence.	This extends the platform into scientific and industrial optimization.
Ecosystem access	SuperQuantumStation supports brand visibility, user engagement, education, and developer access.	It strengthens awareness and partner access without distracting from QMedic as the commercial wedge.

3. Company Overview and Market Context

3.1 Company identity

SQK develops deployable advanced-computing solutions by combining quantum methods, AI, HPC, physics-informed modeling, and secure AI governance. The company focuses on practical deployment, validation, and commercialization rather than speculative claims of near-term quantum advantage.

3.2 Why now

- Medical AI is moving from experimental model development to controlled deployment, increasing the need for quality governance and auditable workflows.
- Quantum and HPC ecosystems are converging through hybrid workloads, creating demand for orchestration and benchmarking layers.
- Enterprise AI adoption is becoming more security-conscious, creating opportunities for secure AI infrastructure and PQC-aware roadmaps.
- Regulated and technically demanding industries prefer measurable reliability, reproducibility, and audit trails over broad claims of accuracy or future advantage.

4. Product Focus: QMedic

QMedic is SQK's lead commercial product. It translates the broader Quantum-AI-HPC platform into a concrete, high-trust use case: medical imaging reconstruction, refinement, comparison, and quality governance.

4.1 Customer problem

- Medical imaging workflows require reliable reconstruction and refinement, not visually plausible but unverified outputs.
- AI-based imaging tools face trust barriers including hallucination risk, reproducibility questions, and workflow integration challenges.
- Hospitals, research institutions, and medical AI companies need measurable quality metrics, side-by-side comparison, and auditable deployment pathways.

4.2 SQK response

- Physics-guided reconstruction and refinement workflows for CT/MRI-oriented use cases.
- Comparison workflow across original, reconstructed, refined, and benchmarked outputs.
- Quality metrics and reporting aligned with QTAU validation methods.
- SaaS/API and enterprise deployment pathways for research, validation, and partner integration.

4.3 Commercialization thesis

QMedic provides the initial market wedge that demonstrates SQK's ability to operationalize high-trust advanced computing in a demanding domain. The product can begin in research and validation settings, expand into paid pilots and API integrations, and evolve toward enterprise deployments as regulatory, clinical, and data-governance requirements are addressed.

5. Platform Foundation Behind QMedic

To avoid investor confusion, SQK's portfolio is presented as one product-led platform. QMedic is the commercial product. The other named assets are platform capabilities that support QMedic and later expansion.

Role in Investor Story	SQK Asset	Function	Investor Value
Commercial Product	QMedic	Medical imaging reconstruction, refinement, comparison, and quality governance.	Near-term monetization and customer validation.
Validation Capability	QTAU	Benchmarking, reproducibility, quality metrics, scorecards, and reporting.	Adoption trust layer and evidence engine.
Execution Capability	Qukkos	Hybrid workflow orchestration across classical, quantum, and HPC resources.	Enterprise workflow infrastructure.
Modeling Capability	QPINN	Physics-informed modeling and optimization for scientific and industrial workloads.	Differentiated technical depth beyond black-box AI.
Ecosystem Capability	SuperQuantumStation	User access, education, developer touchpoints, and partner community entry.	Brand visibility and ecosystem access.

Portfolio Clarity Principle
SQK leads with QMedic. QTAU, Qukkos, QPINN, and SuperQuantumStation are platform foundations and expansion paths, not equally prioritized standalone product lines.

6. Technology Architecture and Differentiation

Architecture Layer	SQK Asset	Primary Function
User / ecosystem	SuperQuantumStation	User access, education, developer and partner touchpoints.
Application	QMedic	Medical imaging workflow, reconstruction/refinement, comparison, and quality metrics.
Modeling / intelligence	QPINN	Physics-informed modeling, simulation-informed learning, and optimization.
Execution / orchestration	Qukkos	Hybrid workflow scheduling and execution across classical, quantum, and HPC resources.
Validation / trust	QTAU	Benchmarking, reproducibility, quality governance, scorecards, and reporting.
Infrastructure	Cloud / on-prem / HPC / quantum access	Flexible deployment and integration foundation.

6.1 Differentiation

- Stack integration: SQK connects validation, orchestration, modeling, and domain deployment instead of selling an isolated model.
- High-trust focus: SQK targets industries where auditability, reproducibility, and quality governance influence purchase decisions.
- Commercial wedge plus platform upside: QMedic leads the near-term story, while QTAU/Qukkos/QPINN increase long-term platform value.
- Deployment flexibility: The platform can support SaaS, API, on-premise, and partner integration models.

7. Milestones and Validation Narrative

SQK's milestones support a credible investor narrative when presented with precise, documented language. The following milestones summarize SQK's public-facing proof points and strategic validation themes.

Year	Milestone	Strategic Meaning
2024	CES award recognition for SuperQuantumStation	Brand and ecosystem visibility.
2025	QWIND Eureka international R&D project	International R&D execution and cross-border collaboration capability.
2026	Strategic investment and ecosystem engagement with named investors and partners	External validation and growth-capital narrative.
2026	IBM Quantum and MathWorks HPC collaboration activities	Global ecosystem linkage and technical credibility.
Multi-year	KISTI quantum-HPC joint R&D and technology transfer activities	Institutional R&D proof point and technology maturity signal.
Project-based	SNU Bundang Hospital CT/MRI-related project activities	Clinical/research workflow credibility.
2026	IT4H project related to medical LLM and PQC architecture	Expansion toward secure medical AI.

8. Business Model and Go-to-Market Strategy

8.1 Revenue model

Asset	Initial Revenue Motion	Expansion Motion	Key Buyer / Partner
QMedic	Research SaaS, paid pilots, API access, project-based deployments.	Hospital/enterprise license, OEM imaging partner integration, regulated workflow modules.	Hospitals, medical AI companies, imaging research groups, PACS/OHIF ecosystem partners.
QTAU	Benchmarking reports, validation service, enterprise PoC support.	Annual license, audit/report module, platform validation subscription.	Enterprises adopting quantum/AI/HPC workflows, research institutes, cloud/HPC partners.
Qukkos	Hybrid workflow integration projects.	Enterprise workflow engine and managed orchestration.	HPC centers, quantum ecosystem partners, enterprise R&D teams.
QPINN	Specialized R&D and modeling projects.	Domain-specific optimization licenses and simulation modules.	Industrial companies, scientific computing teams, energy/manufacturing partners.
SuperQuantumStation	Subscription, education, developer access.	Ecosystem programs, partner marketplace, user acquisition funnel.	Students, developers, institutions, partner communities.

8.2 Go-to-market sequence

1. Lead with QMedic: use one clearly defined medical imaging product to open commercial conversations.
2. Attach QTAU to QMedic: package quality metrics, benchmark reports, and evidence generation as part of the trust layer.
3. Convert project credibility into paid pilots: target hospitals, research labs, medical AI companies, and HPC/quantum partners.
4. Package repeatable modules: dashboards, APIs, benchmark reports, connectors, and deployment playbooks.
5. Expand into enterprise licensing: offer SaaS/API/on-premise packages with recurring support and integration contracts.
6. Use SuperQuantumStation as an ecosystem and partner channel rather than the primary enterprise sales story.

9. Growth Roadmap and Use of Proceeds

Timeframe	Commercial Focus	Product Focus	Investor KPI
0-12 months	QMedic pilot pipeline, investor website, collateral, case studies.	QMedic MVP/PoC packaging, QTAU benchmark reports, integrated demo assets.	Pilot pipeline, LOIs/MOUs, demo conversion, benchmark reports.
12-24 months	Convert pilots into paid recurring contracts and API usage.	QMedic SaaS/API, QTAU enterprise validation, Qukkos workflow integration.	Contracted revenue, active deployments, partner integrations.
24-36 months	Scale platform revenue and expand globally.	Cross-solution integration and secure medical AI stack with PQC.	Enterprise licenses, OEM relationships, gross margin, renewal rate.

9.1 Use of proceeds categories

- Productization: QMedic SaaS/API hardening, QTAU report automation, integration connectors, and deployment tooling.
- Validation: data partnerships, pilot support, benchmark studies, documentation, and quality-management preparation.
- Engineering: platform architecture, security, MLOps/HPC integration, scalable backend, and user-facing dashboards.
- Commercialization: enterprise sales, partner development, investor relations, and market-entry materials.
- Governance and compliance: privacy controls, security reviews, legal review, claim substantiation, and regulatory pathway preparation where applicable.

10. Risk Management

Risk	Investor Concern	Mitigation
Portfolio complexity	Too many product names may dilute focus.	Lead with QMedic and present all other assets as platform capabilities.
Quantum hype risk	Investors may distrust broad quantum claims.	Use benchmark-specific language and avoid unsupported advantage claims.
Clinical/regulatory risk	Medical claims require careful wording and validation.	Position QMedic for research, validation, workflow, and quality governance unless regulatory approvals exist.
Commercialization risk	Project revenue may not convert into recurring revenue.	Package repeatable SaaS/API/license modules and track pilot-to-contract conversion.
Partner disclosure risk	Named partners may require approval.	Use partner names only where public disclosure or written permission is available.
Execution risk	Deep-tech productization is resource-intensive.	Prioritize product hardening, deployment playbooks, and measurable KPIs.

11. Investor Thesis and Conclusion

Investor Thesis

SQK is building a validated Quantum-AI-HPC platform for high-trust industries, with QMedic as the near-term commercial wedge and QTAU/Qukkos/QPINN as reusable platform capabilities that compound over time.

The strongest investor message is disciplined and product-led: SQK is not simply a quantum startup and not a collection of unrelated tools. It is a high-trust advanced-computing platform company with a focused medical imaging entry point and

reusable technical assets that can expand into scientific computing, industrial optimization, hybrid HPC, and secure medical AI.

- QMedic gives SQK a concrete product narrative and commercial wedge.
- QTAU provides evidence, benchmarking, and trust required for adoption.
- Qukkos and QPINN add platform depth for hybrid execution and physics-informed modeling.
- SuperQuantumStation supports ecosystem access and brand visibility without distracting from enterprise sales focus.

Appendix A. One-Page Investor Summary

Category	Investor-Ready Message
Company	SQK is a Quantum-AI-HPC platform company building validated, secure, and deployable advanced-computing solutions for high-trust industries.
Commercial wedge	QMedic: CT/MRI-oriented reconstruction, refinement, comparison, and quality-governance platform.
Platform foundation	QTAU validates; Qukkos orchestrates; QPINN models; SuperQuantumStation creates ecosystem access.
Why now	Medical AI, HPC, and quantum-adjacent workflows need reliability, reproducibility, security, and governance to move from research to operations.
Business model	SaaS, API, enterprise license, benchmarking service, R&D-to-product conversion, and OEM/platform partnerships.
Moat	Connected platform assets, trust layer, validation workflows, medical imaging wedge, and partner ecosystem.
Immediate priorities	QMedic pilots, QTAU benchmark reports, partner case studies, integrated demo, investor data room, and claim verification.